{
    "clinical_study": {
        "@rank": "97503", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "50 mg  SP2086", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "100 mg SP2086", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "200 mg SP2086", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "100 mg Sitagliptin", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to explore the\n      effective dose range of SP2086 in Patients with type 2 diabetes."
        }, 
        "brief_title": "A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes", 
        "completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  20 Years to 70 Years ,Male and Female diagnosed with type 2 diabetes mellitus\n\n          -  Patients not on an oral antihyperglycemic agent (OHA) with 7.0% \u2264HbA1C \u226410.5%,or not\n             on an OHA for 3 months with 7.0% \u2264HbA1C \u226410.5%\n\n          -  BMI 19~35 kg/m2\n\n        Exclusion Criteria:\n\n          -  Patient has history of type 1 diabetes mellitus\n\n          -  Patient has history of ketoacidosis\n\n          -  Patient has history of severe unconscious hypoglycemosis\n\n          -  Patient has history of acute and chronic pancreatitis or pancreatic injury that may\n             lead to high risk of pancreatitis\n\n          -  Patient has history of decompensated heart failure (NYHA class III and IV), unstable\n             angina, stroke or transient ischemic attack, myocardial infarction, persistence and\n             clinical\n\n          -  Patient has history of a history of hypertension, and after antihypertensive\n             treatment, systolic blood pressure \u2265 160 mmHg or diastolic blood pressure \u2265 100 mmHg\n\n          -  Patient has severe liver or kidney disease,alanine aminotransferase >2\u00d7UNL, Aspartate\n             Aminotransferase >2\u00d7upper normal limit(UNL)\uff1btotal bilirubin >2\u00d7UNL\uff1b creatinine>1.5\n             mg/dL (Male,132.6\u03bcmol/L) \uff0c>1.4 mg/dL(Female\uff0c123.8\u03bcmol/L)\n\n          -  Patient has severe chronic gastrointestinal disease or therapy that may affect drug\n             absorption, such as gastrointestinal surgery\n\n          -  Patient has severe haematological diseases or other diseases leading to hemolyze and\n             red blood cell unstable (malaria\u3001haemolytic anaemia eg. )\n\n          -  Patient has other endocrine diseases, for example\n             hyperthyroidism\u3001hypothyroidism\u3001hypercortisolism\u3001multiple endocrine neoplasia and so\n             on\n\n          -  Patient has history of malignancy\n\n          -  Patient has history of alcohol or drug abuse"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01969357", 
            "org_study_id": "HR-SP-201"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Tablets(n=4),once daily for 84 days", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "50 mg  SP2086", 
                "description": "Tablets(n=1),50mg strength+tablets(n=3) 0 mg once daily for 84 days", 
                "intervention_name": "50 mg SP2086", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "100 mg SP2086", 
                "description": "Tablets(n=1),100 mg strength+tablets(n=3) once 0 mg daily for 84 days", 
                "intervention_name": "100 mg SP2086", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "200 mg SP2086", 
                "description": "Tablets(n=2),100 mg strength+tablets(n=2) 0mg once daily for 84 days", 
                "intervention_name": "200 mg SP2086", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "100 mg Sitagliptin", 
                "description": "Tablets(n=1),100 mg strength+tablets(n=3),0 mg strength once daily for 84 days", 
                "intervention_name": "100 mg Sitagliptin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sitagliptin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Sp2086", 
            "Phase II", 
            "monotherapy"
        ], 
        "lastchanged_date": "October 21, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "Chinese PLA General Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Multicenter Randomized, Double-blind, Placebo and Positive Controlled ,Parallel Group ,Phase II Study to Access the Efficacy and Safety of SP2086 Treated Type 2 Diabetes Patients", 
        "overall_official": {
            "affiliation": "Chinese PLA General Hospital", 
            "last_name": "Changyu Pan, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "the change from baseline in HbA1c at 12 week", 
            "safety_issue": "No", 
            "time_frame": "baseline, week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01969357"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of Participants Achieving Less Than (<) 6.5% or <7% HbA1c Levels", 
                "safety_issue": "No", 
                "time_frame": "week 12"
            }, 
            {
                "measure": "Change From Baseline in Fasting Plasma Glucose at Week 4, 8 and 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week  4, 8, 12"
            }, 
            {
                "measure": "Post-meal total and incremental glucose,insulin and C-peptide area under the  curve at week 4 ,12", 
                "safety_issue": "No", 
                "time_frame": "baseline, week 4 ,12"
            }, 
            {
                "measure": "Change from baseline in Homeostasis model assessment-beta(HOMA-\u03b2) at week 4,week12", 
                "safety_issue": "No", 
                "time_frame": "baseline, week 4,12week"
            }, 
            {
                "measure": "Change From Baseline in lipid at Week 4, 8 and 12", 
                "safety_issue": "No", 
                "time_frame": "baseline, week 4, 8, 12"
            }, 
            {
                "measure": "Change From Baseline in Body Weight at Week 4,8,12", 
                "safety_issue": "No", 
                "time_frame": "baseline, Week 4, 8,12"
            }
        ], 
        "source": "Jiangsu HengRui Medicine Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu HengRui Medicine Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}